Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

• Published in: PloS one Vol. 19; no. 8; p. e0308812
• Main Authors: Irving, Adam, Petrie, Dennis, Harris, Anthony, Fanning, Laura, Wood, Erica M, Moore, Elizabeth, Wellard, Cameron, Waters, Neil, Huynh, Kim, Augustson, Bradley, Cook, Gordon, Gay, Francesca, McCaughan, Georgia, Mollee, Peter, Spencer, Andrew, McQuilten, Zoe K
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 27.08.2024; Public Library of Science (PLoS)
• Subjects: Adult; Aged; Aged, 80 and over; Australia; Bone marrow; Bone marrow transplantation; Cancer; Care and treatment; Chemotherapy; Clinical trials; Committees; Computer Simulation; Computer-generated environments; Decision making; Diagnosis; Discrete event systems; Disease; Diseases; Drug therapy; Economic forecasting; Female; Health services; Humans; Life expectancy; Life span; Male; Malignancy; Medical diagnosis; Medical prognosis; Medical research; Medicine and Health Sciences; Medicine, Experimental; Middle Aged; Missing data; Multiple myeloma; Multiple Myeloma - therapy; New Zealand; Patients; Prognosis; Registries; Registries (in medicine); Reimbursement; Research and Analysis Methods; Simulation; Simulation models; Stem cell transplantation; Stem cells; Systematic review; Transplantation; Treatment Outcome; New Zealand; Australia
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0308812

Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years. However, clinical trials are unable to provide patients and clinicians with long-term prognostic information nor policymakers with the full body of evidence needed to perform economic evaluation of new therapies or make reimbursement decisions. To address these limitations of the available evidence, this study aimed to develop and validate the EpiMAP Myeloma model, a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways. Risk equations were estimated using the Australian and New Zealand Myeloma & Related Diseases Registry after multiple imputation of missing data. Risk equation coefficients were combined with multiple myeloma patients at diagnosis from the Registry to perform the simulation. The model was validated with 100 bootstraps of an out-of-sample prediction analysis using a 70/30 split of the 4,121 registry patients diagnosed between 2009 and 2023, resulting in 2,884 and 1,237 patients in the training and validation cohorts, respectively. For 90% of the 120 months in the 10-year post-diagnosis period, there was no significant difference in overall survival between the validation and simulated cohorts. These results highlight that the EpiMAP Myeloma model is robust at predicting multiple myeloma disease outcomes and treatment pathways in Australia & New Zealand. In the future, clinicians will be able to use the EpiMAP Myeloma model to provide personalised estimates of life expectancy to patients based on their specific characteristics, disease stage, and response to treatment. Policymakers will also be able to use the model to perform economic evaluation, to forecast the number of patients receiving treatment at different stages, and to determine the downstream impact of listing new, effective therapies.